Synthesis of novel chitosan-g-PNVCL nanofibers coated with gold-gold sulfide nanoparticles for controlled release of cisplatin and treatment of MCF-7 breast cancer

Delivery of paclitaxel by carboxymethyl chitosan-functionalized dendritic fibrous nano-silica: Fabrication, characterization, controlled release performance and pharmacokinetics

In this study, carboxymethyl chitosan (CMCS) with excellent biocompatibility was used as the "gatekeeper" to design and fabricate a pH-responsive drug delivery system (CMCS-DFNS) as paclitaxel carriers. Characterization results showed that CMCS-DFNS was successfully prepared and the nanocarriers displayed excellent drug loading efficiency of 19.8 %, and the results of the adsorption mechanism revealed that the adsorption of PTX was consistent with the Freundlich isotherm and pseudo-second-order kinetic model. Furthermore, the pH-responsive controlled release behavior at different pH (pH = 7.4, 6.5, and 5.0) was evaluated, and the results demonstrated that the cumulative release at pH 5.0 was 58.8 %, which was 2.7 times higher than that at pH 7.4, suggesting that the carrier exhibited a good pH sensitivity. The results of in vitro cellular experiments further indicated that CMCS-DFNS significantly improved the drug uptake efficiency in breast cancer MCF-7 cells. Importantly, the results of in vivo and cellular pharmacokinetic revealed that CMCS-DFNS can improve the circulation time and enhance the relative bioavailability of paclitaxel. Therefore, the fabricated pH-responsive drug delivery system has potential applications in the delivery of anti-tumor drugs, and provides a new delivery pathway for other compounds with low bioavailability.

Nanofibrous drug delivery systems for breast cancer: a review

Breast cancer is the most common type of cancer among women. Breast-conserving surgery (BCS) is one of the preferred approaches for treating non-invasive or early-stage breast cancers. However, local-regional recurrence (LRR) is one of the critical risk factors after BCS. As many as 10%-20% of BCS cases may show LRR within 5 years and almost 50% within 10 years after surgery. Radiation therapy is one of the preferred treatments used to prevent LRR after BCS. However, because of possible side-effects of radiation therapy, targeted drug delivery systems (DDS) based on nanofibers loaded with anti-cancer drugs have been explored in recent years to control LRR. This paper aims to review different polymers and anti-cancer drugs used for developing nanofibrous DDS against various breast cancer cell lines for their efficacy and advantages. It was observed that the utilization of nanofibers scaffolds after mastectomy could decrease the recurrence of breast cancer cells to a great extent as these nanofibrous scaffolds release drugs in a sustained manner for a prolonged time eliminating the need for radiations. Besides, the side effects of chemotherapy or other aggressive anticancer treatment on healthy cells could also be avoided.

Thermoresponsive Chitosan-Grafted-Poly(N-vinylcaprolactam) Microgels via Ionotropic Gelation for Oncological Applications

Microgels can be considered soft, porous and deformable particles with an internal gel structure swollen by a solvent and an average size between 100 and 1000 nm. Due to their biocompatibility, colloidal stability, their unique dynamicity and the permeability of their architecture, they are emerging as important candidates for drug delivery systems, sensing and biocatalysis. In clinical applications, the research on responsive microgels is aimed at the development of "smart" delivery systems that undergo a critical change in conformation and size in reaction to a change in environmental conditions (temperature, magnetic fields, pH, concentration gradient). Recent achievements in biodegradable polymer fabrication have resulted in new appealing strategies, including the combination of synthetic and natural-origin polymers with inorganic nanoparticles, as well as the possibility of controlling drug release remotely. In this review, we provide a literature review on the use of dual and multi-responsive chitosan-grafted-poly-(N-vinylcaprolactam) (CP) microgels in drug delivery and oncological applications.

A review on allopathic and herbal nanofibrous drug delivery vehicles for cancer treatments

Drug delivery empowered with nanotechnology manifests to be a superior therapy to cancer. Electrospun nanofibers cocooning anti-cancerous drugs have shown tremendous cytotoxicity towards various tumor cells, including breast, brain, liver, and lung cancer cells. This pristine drug delivery system, according to literature, desists showing any undesirable effects on other parts of the body and bestows several other benefits. From nature-derived Curcumin to laboratory-made Doxorubicin, literature proclaims many such drugs used in nanofibrous drug delivery. Also, multi-drug delivery has been reported to exhibit enhanced properties. The present review exhibits the unrealized potential of nanofibrous drug delivery in chemotherapy.

A review on the applications of electrospun chitosan nanofibers for the cancer treatment

In recent years, the incidence of cancer is increasing every day due to poor quality of life (industrialization of life). Therefore, the treatment of cancer has received much attention from therapists. So far, many anticancer drugs have been used to treat cancer patents. However, the direct use of the anticancer drugs has the adverse side effects for patents and several limitations to treat process. Natural chitosan nanofibers prepared by electrospinning method have unique properties such as high surface area, high porosity, suitable mechanical properties, nontoxicity, biocompatibility, biodegradability, biorenewable, low immunogenicity, better clinical functionality, analogue to extracellular model, and easy production in large scale. Therefore, this bio-polymer is a very suitable case to deliver of the anti-cancer drugs to treat cancer patents. In this review summarizes the electrospinning synthesis of chitosan and its therapeutic application for the various cancer treatment.